Ann Oncol: Most-Read Full-Text Articles
http://annonc.oxfordjournals.org/
Most-read rankings are recalculated at the beginning of the month based on usage of full-text and PDF views for the previous month.2009-11-14<![CDATA[Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/8/1319?rss=1&ssource=mfc
Aug 1, 2009; 20:1319-1329 ]]>A. Goldhirsch, J. N. Ingle, R. D. Gelber, A. S. Coates, B. Thurlimann, H.-J. Senn, Panel members2009-08-01Oxford University Press<![CDATA[Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/suppl_4/iv10?rss=1&ssource=mfc
May 1, 2009; 20:10-14 ESMO clinical recommendations]]>V. Kataja, M. Castiglione, On behalf of the ESMO Guidelines Working Group2009-05-01Oxford University Press<![CDATA[Cancer and thrombosis: implications of published guidelines for clinical practice]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/10/1619?rss=1&ssource=mfc
Oct 1, 2009; 20:1619-1630 ]]>A. A. Khorana2009-10-01Oxford University Press<![CDATA[Estimates of the cancer incidence and mortality in Europe in 2006]]>
http://annonc.oxfordjournals.org/cgi/content/short/18/3/581?rss=1&ssource=mfc
Mar 1, 2007; 18:581-592 ]]>J Ferlay, P Autier, M Boniol, M Heanue, M Colombet, P Boyle2007-03-01Oxford University Press<![CDATA[Artificial sweeteners--do they bear a carcinogenic risk?]]>
http://annonc.oxfordjournals.org/cgi/content/short/15/10/1460?rss=1&ssource=mfc
Oct 1, 2004; 15:1460-1465 Reviews]]>M. R. Weihrauch, V. Diehl2004-10-0110.1093/annonc/mdh256Oxford University Press<![CDATA[Assessing prognosis in patients with chronic lymphocytic leukemia a quarter of a century after Rai and Binet staging systems]]>
http://annonc.oxfordjournals.org/cgi/content/short/15/10/1450?rss=1&ssource=mfc
Oct 1, 2004; 15:1450-1451 Editorials]]>E. Montserrat2004-10-0110.1093/annonc/mdh408Oxford University Press<![CDATA[Non-small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/suppl_4/iv68?rss=1&ssource=mfc
May 1, 2009; 20:68-70 ESMO clinical recommendations]]>G. D''Addario, E. Felip, On behalf of the ESMO Guidelines Working Group2009-05-01Oxford University Press<![CDATA[Primary colon cancer: ESMO Clinical Recommendations for diagnosis, adjuvant treatment and follow-up]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/suppl_4/iv49?rss=1&ssource=mfc
May 1, 2009; 20:49-50 ESMO clinical recommendations]]>E. Van Cutsem, J. Oliveira, On behalf of the ESMO Guidelines Working Group2009-05-01Oxford University Press<![CDATA[The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/8/1303?rss=1&ssource=mfc
Aug 1, 2009; 20:1303-1317 ]]>E. Terpos, O. Sezer, P. I. Croucher, R. Garcia-Sanz, M. Boccadoro, J. San Miguel, J. Ashcroft, J. Blade, M. Cavo, M. Delforge, M.-A. Dimopoulos, T. Facon, M. Macro, A. Waage, P. Sonneveld2009-08-01Oxford University Press<![CDATA[Locally recurrent or metastatic breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/suppl_4/iv15?rss=1&ssource=mfc
May 1, 2009; 20:15-18 ESMO clinical recommendations]]>F. Cardoso, M. Castiglione, On behalf of the ESMO Guidelines Working Group2009-05-01Oxford University Press<![CDATA[Gastric cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/suppl_4/iv34?rss=1&ssource=mfc
May 1, 2009; 20:34-36 ESMO clinical recommendations]]>C. Jackson, D. Cunningham, J. Oliveira, On behalf of the ESMO Guidelines Working Group2009-05-01Oxford University Press<![CDATA[Management of febrile neutropenia: ESMO Clinical Recommendations]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/suppl_4/iv166?rss=1&ssource=mfc
May 1, 2009; 20:166-169 ESMO clinical recommendations]]>F. Marti Marti, M. H. Cullen, F. Roila, On behalf of the ESMO Guidelines Working Group2009-05-01Oxford University Press<![CDATA[Cancer incidence and mortality in Europe, 2004]]>
http://annonc.oxfordjournals.org/cgi/content/short/16/3/481?rss=1&ssource=mfc
Mar 1, 2005; 16:481-488 Epidemiology]]>P. Boyle, J. Ferlay2005-03-01Oxford University Press<![CDATA[Advanced colorectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/suppl_4/iv61?rss=1&ssource=mfc
May 1, 2009; 20:61-63 ESMO clinical recommendations]]>E. Van Cutsem, J. Oliveira, On behalf of the ESMO Guidelines Working Group2009-05-01Oxford University Press<![CDATA[Multiple myeloma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/suppl_4/iv97?rss=1&ssource=mfc
May 1, 2009; 20:97-99 ESMO clinical recommendations]]>J.-L. Harousseau, M. Dreyling, On behalf of the ESMO Guidelines Working Group2009-05-01Oxford University Press<![CDATA[Pancreatic cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/suppl_4/iv37?rss=1&ssource=mfc
May 1, 2009; 20:37-40 ESMO clinical recommendations]]>S. Cascinu, S. Jelic, On behalf of the ESMO Guidelines Working Group2009-05-01Oxford University Press<![CDATA[Renal cell carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/suppl_4/iv81?rss=1&ssource=mfc
May 1, 2009; 20:81-82 ESMO clinical recommendations]]>B. Escudier, V. Kataja, On behalf of the ESMO Guidelines Working Group2009-05-01Oxford University Press<![CDATA[Rectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/suppl_4/iv54?rss=1&ssource=mfc
May 1, 2009; 20:54-56 ESMO clinical recommendations]]>B. Glimelius, J. Oliveira, On behalf of the ESMO Guidelines Working Group2009-05-01Oxford University Press<![CDATA[Prostate cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/suppl_4/iv76?rss=1&ssource=mfc
May 1, 2009; 20:76-78 ESMO clinical recommendations]]>A. Horwich, C. Parker, V. Kataja, On behalf of the ESMO Guidelines Working Group2009-05-01Oxford University Press<![CDATA[Third consensus on medical treatment of metastatic breast cancer]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/11/1771?rss=1&ssource=mfc
Nov 1, 2009; 20:1771-1785 ]]>S. Beslija, J. Bonneterre, H. J. Burstein, V. Cocquyt, M. Gnant, V. Heinemann, J. Jassem, W. J. Kostler, M. Krainer, S. Menard, T. Petit, L. Petruzelka, K. Possinger, P. Schmid, E. Stadtmauer, M. Stockler, S. Van Belle, C. Vogel, N. Wilcken, C. Wiltschke, C. C. Zielinski, H. Zwierzina, for the Central European Cooperative Oncology Group (CECOG)2009-11-01Oxford University Press<![CDATA[The role of VEGF in triple-negative breast cancer: where do we go from here?]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/10/1615?rss=1&ssource=mfc
Oct 1, 2009; 20:1615-1617 ]]>S. F. Dent2009-10-01Oxford University Press<![CDATA[Gastrointestinal stromal tumours: ESMO Clinical Recommendations for diagnosis, treatment and follow-up]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/suppl_4/iv64?rss=1&ssource=mfc
May 1, 2009; 20:64-67 ESMO clinical recommendations]]>P. G. Casali, L. Jost, P. Reichardt, M. Schlemmer, J.-Y. Blay, On behalf of the ESMO Guidelines Working Group2009-05-01Oxford University Press<![CDATA[Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/8/1420?rss=1&ssource=mfc
Aug 1, 2009; 20:1420-1433 ]]>H. Breivik, N. Cherny, B. Collett, F. de Conno, M. Filbet, A. J. Foubert, R. Cohen, L. Dow2009-08-01Oxford University Press<![CDATA[Esophageal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/suppl_4/iv32?rss=1&ssource=mfc
May 1, 2009; 20:32-33 ESMO clinical recommendations]]>M. Stahl, J. Oliveira, On behalf of the ESMO Guidelines Working Group2009-05-01Oxford University Press<![CDATA[Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer]]>
http://annonc.oxfordjournals.org/cgi/content/short/mdp392v1?rss=1&ssource=mfc
Oct 14, 2009; 0:3921-392 ]]>K. N. Syrigos, J. Vansteenkiste, P. Parikh, J. von Pawel, C. Manegold, R. G. Martins, L. Simms, K. P. Sugarman, C. Visseren-Grul, G. V. Scagliotti2009-10-14Oxford University Press<![CDATA[Differentiated thyroid cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/suppl_4/iv143?rss=1&ssource=mfc
May 1, 2009; 20:143-146 ESMO clinical recommendations]]>F. Pacini, M. G. Castagna, L. Brilli, G. Pentheroudakis, On behalf of the ESMO Guidelines Working Group2009-05-01Oxford University Press<![CDATA[Squamous cell carcinoma of the head and neck: ESMO Clinical Recommendations for diagnosis, treatment and follow-up]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/suppl_4/iv121?rss=1&ssource=mfc
May 1, 2009; 20:121-122 ESMO clinical recommendations]]>L. Licitra, E. Felip, On behalf of the ESMO Guidelines Working Group2009-05-01Oxford University Press<![CDATA[HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target]]>
http://annonc.oxfordjournals.org/cgi/content/short/19/9/1523?rss=1&ssource=mfc
Sep 1, 2008; 19:1523-1529 ]]>C. Gravalos, A. Jimeno2008-09-01Oxford University Press<![CDATA[Estimates of the cancer incidence and mortality in Europe in 2006]]>
http://annonc.oxfordjournals.org/cgi/content/short/mdl498v1?rss=1&ssource=mfc
Mar 1, 2007; 18:581-592 ]]>J Ferlay, P Autier, M Boniol, M Heanue, M Colombet, P Boyle2007-03-01Oxford University Press<![CDATA[Prevention of chemotherapy-induced hair loss by scalp cooling]]>
http://annonc.oxfordjournals.org/cgi/content/short/16/3/352?rss=1&ssource=mfc
Mar 1, 2005; 16:352-358 Reviews]]>E. G. Grevelman, W. P. M. Breed2005-03-01Oxford University Press<![CDATA[Newly and relapsed epithelial ovarian carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/suppl_4/iv21?rss=1&ssource=mfc
May 1, 2009; 20:21-23 ESMO clinical recommendations]]>S. Aebi, M. Castiglione, On behalf of the ESMO Guidelines Working Group2009-05-01Oxford University Press<![CDATA[Malignant glioma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/suppl_4/iv126?rss=1&ssource=mfc
May 1, 2009; 20:126-128 ESMO clinical recommendations]]>R. Stupp, F. Roila, On behalf of the ESMO Guidelines Working Group2009-05-01Oxford University Press<![CDATA[author index]]>
http://annonc.oxfordjournals.org/cgi/content/short/17/suppl_11/xi89?rss=1&ssource=mfc
Nov 1, 2006; 17:89-98 ]]>2006-11-0110.1093/annonc/mdl429Oxford University Press<![CDATA[Palliative sedation therapy does not hasten death: results from a prospective multicenter study]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/7/1163?rss=1&ssource=mfc
Jul 1, 2009; 20:1163-1169 quality of life/supportive care/palliative care]]>M. Maltoni, C. Pittureri, E. Scarpi, L. Piccinini, F. Martini, P. Turci, L. Montanari, O. Nanni, D. Amadori2009-07-01Oxford University Press<![CDATA[Soft tissue sarcomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/suppl_4/iv132?rss=1&ssource=mfc
May 1, 2009; 20:132-136 ESMO clinical recommendations]]>P. G. Casali, L. Jost, S. Sleijfer, J. Verweij, J.-Y. Blay, On behalf of the ESMO Guidelines Working Group2009-05-01Oxford University Press<![CDATA[An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer]]>
http://annonc.oxfordjournals.org/cgi/content/short/mdp373v1?rss=1&ssource=mfc
Nov 2, 2009; 0:3732-373 ]]>G. Capri, J. Chang, S.-C. Chen, P. Conte, K. Cwiertka, G. Jerusalem, Z. Jiang, S. Johnston, B. Kaufman, J. Link, J. Ro, J. Schutte, C. Oliva, R. Parikh, A. Preston, J. Rosenlund, M. Selzer, D. Zembryki, S. De Placido2009-11-02Oxford University Press<![CDATA[BRCA in breast cancer: ESMO Clinical Recommendations]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/suppl_4/iv19?rss=1&ssource=mfc
May 1, 2009; 20:19-20 ESMO clinical recommendations]]>J. Balmana, O. Diez, M. Castiglione, On behalf of the ESMO Guidelines Working Group2009-05-01Oxford University Press<![CDATA[Breast carcinoma--rare types: review of the literature]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/11/1763?rss=1&ssource=mfc
Nov 1, 2009; 20:1763-1770 ]]>R. Yerushalmi, M. M. Hayes, K. A. Gelmon2009-11-01Oxford University Press<![CDATA[HDAC inhibitor-based therapies and haematological malignancy]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/8/1293?rss=1&ssource=mfc
Aug 1, 2009; 20:1293-1302 ]]>L. Stimson, V. Wood, O. Khan, S. Fotheringham, N. B. La Thangue2009-08-01Oxford University Press<![CDATA[Hepatocellular carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/suppl_4/iv41?rss=1&ssource=mfc
May 1, 2009; 20:41-45 ESMO clinical recommendations]]>S. Jelic, On behalf of the ESMO Guidelines Working Group2009-05-01Oxford University Press<![CDATA[Cutaneous malignant melanoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/suppl_4/iv129?rss=1&ssource=mfc
May 1, 2009; 20:129-131 ESMO clinical recommendations]]>R. Dummer, A. Hauschild, G. Pentheroudakis2009-05-01Oxford University Press<![CDATA[Management of cancer pain: ESMO Clinical Recommendations]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/suppl_4/iv170?rss=1&ssource=mfc
May 1, 2009; 20:170-173 ESMO clinical recommendations]]>L. Jost, F. Roila, On behalf of the ESMO Guidelines Working Group2009-05-01Oxford University Press<![CDATA[Invasive bladder cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/suppl_4/iv79?rss=1&ssource=mfc
May 1, 2009; 20:79-80 ESMO clinical recommendations]]>J. Bellmunt, S. Albiol, V. Kataja, On behalf of the ESMO Guidelines Working Group2009-05-01Oxford University Press<![CDATA[Cervical cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/suppl_4/iv27?rss=1&ssource=mfc
May 1, 2009; 20:27-28 ESMO clinical recommendations]]>C. Haie-Meder, P. Morice, M. Castiglione, On behalf of the ESMO Guidelines Working Group2009-05-01Oxford University Press<![CDATA[Small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/suppl_4/iv71?rss=1&ssource=mfc
May 1, 2009; 20:71-72 ESMO clinical recommendations]]>M. Sorensen, E. Felip, On behalf of the ESMO Guidelines Working Group2009-05-01Oxford University Press<![CDATA[Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients]]>
http://annonc.oxfordjournals.org/cgi/content/short/15/2/291?rss=1&ssource=mfc
Feb 1, 2004; 15:291-295 Miscellaneous tumors]]>G. M. Marx, G. M. Blake, E. Galani, C. B. Steer, S. E. Harper, K. L. Adamson, D. L. Bailey, P. G. Harper2004-02-0110.1093/annonc/mdh079Oxford University Press<![CDATA[Artificial sweeteners and cancer risk in a network of case-control studies]]>
http://annonc.oxfordjournals.org/cgi/content/short/18/1/40?rss=1&ssource=mfc
Jan 1, 2007; 18:40-44 ]]>S Gallus, L Scotti, E Negri, R Talamini, S Franceschi, M Montella, A Giacosa, L Dal Maso, C La Vecchia2007-01-01Oxford University Press<![CDATA[Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/6/985?rss=1&ssource=mfc
Jun 1, 2009; 20:985-992 ]]>B. Nordlinger, E. Van Cutsem, T. Gruenberger, B. Glimelius, G. Poston, P. Rougier, A. Sobrero, M. Ychou, on behalf of the European Colorectal Metastases Treatment Group2009-06-01Oxford University Press<![CDATA[Testicular seminoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/suppl_4/iv83?rss=1&ssource=mfc
May 1, 2009; 20:83-88 ESMO clinical recommendations]]>H.-J. Schmoll, K. Jordan, R. Huddart, M. P. Laguna, A. Horwich, K. Fizazi, V. Kataja, On behalf of the ESMO Guidelines Working Group2009-05-01Oxford University Press<![CDATA[Chemotherapy-induced nausea and vomiting: ESMO Clinical Recommendations for prophylaxis]]>
http://annonc.oxfordjournals.org/cgi/content/short/20/suppl_4/iv156?rss=1&ssource=mfc
May 1, 2009; 20:156-158 ESMO clinical recommendations]]>J. Herrstedt, F. Roila, On behalf of the ESMO Guidelines Working Group2009-05-01Oxford University Press